In melanoma patients, the sequential administration of an attenuated herpes simplex virus type 1 (HVS-1), and an anti-PD-1 therapy resulted in a 33% complete response rate, with increased CD8+ T cells, PDL1 protein and IFNg gene expression in responders. Here, CD274 is linked to melanoma.